191 related articles for article (PubMed ID: 21431297)
1. Prognostic factor analysis of third-line chemotherapy in patients with advanced gastric cancer.
Shim HJ; Yun JY; Hwang JE; Bae WK; Cho SH; Chung IJ
Gastric Cancer; 2011 Aug; 14(3):249-56. PubMed ID: 21431297
[TBL] [Abstract][Full Text] [Related]
2. Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival.
Kang EJ; Im SA; Oh DY; Han SW; Kim JS; Choi IS; Kim JW; Kim YJ; Kim JH; Kim TY; Lee JS; Bang YJ; Lee KW
Gastric Cancer; 2013 Oct; 16(4):581-9. PubMed ID: 23266882
[TBL] [Abstract][Full Text] [Related]
3. A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy.
Kanagavel D; Pokataev IA; Fedyanin MY; Tryakin AA; Bazin IS; Narimanov MN; Yakovleva ES; Garin AM; Tjulandin SA
Ann Oncol; 2010 Sep; 21(9):1779-1785. PubMed ID: 20150573
[TBL] [Abstract][Full Text] [Related]
4. Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300.
Bang YJ; Ruiz EY; Van Cutsem E; Lee KW; Wyrwicz L; Schenker M; Alsina M; Ryu MH; Chung HC; Evesque L; Al-Batran SE; Park SH; Lichinitser M; Boku N; Moehler MH; Hong J; Xiong H; Hallwachs R; Conti I; Taieb J
Ann Oncol; 2018 Oct; 29(10):2052-2060. PubMed ID: 30052729
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer.
Hwang JE; Kim HN; Kim DE; Choi HJ; Jung SH; Shim HJ; Bae WK; Hwang EC; Cho SH; Chung IJ
BMC Cancer; 2011 Nov; 11():489. PubMed ID: 22103888
[TBL] [Abstract][Full Text] [Related]
6. The prognostic significance of the increase in the serum M30 and M65 values after chemotherapy and relationship between these values and clinicopathological factors in patients with advanced gastric cancer.
Bilici A; Ustaalioglu BB; Ercan S; Seker M; Yilmaz BE; Orcun A; Gumus M
Tumour Biol; 2012 Dec; 33(6):2201-8. PubMed ID: 22890829
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study.
Bang YJ; Kang YK; Catenacci DV; Muro K; Fuchs CS; Geva R; Hara H; Golan T; Garrido M; Jalal SI; Borg C; Doi T; Yoon HH; Savage MJ; Wang J; Dalal RP; Shah S; Wainberg ZA; Chung HC
Gastric Cancer; 2019 Jul; 22(4):828-837. PubMed ID: 30911859
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin as first-line chemotherapy in patients with advanced gastric cancer.
Wang F; Wang Z; Zhou N; An X; Xu R; He Y; Li Y
Am J Clin Oncol; 2011 Aug; 34(4):401-5. PubMed ID: 21791984
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel and Cisplatin Plus Fluorouracil compared with Modified Docetaxel, Cisplatin, and 5-Fluorouracil as first-line therapy for advanced gastric cancer: a retrospective analysis of single institution.
Inal A; Kaplan MA; Kucukoner M; Isikdogan A
Neoplasma; 2012; 59(2):233-6. PubMed ID: 22248282
[TBL] [Abstract][Full Text] [Related]
10. Is pathologic tumor regression grade after neo-adjuvant chemotherapy a promising prognostic indicator for patients with locally advanced gastric cancer? A cohort study evaluating tumor regression response.
Xu X; Zheng G; Zhang T; Zhao Y; Zheng Z
Cancer Chemother Pharmacol; 2019 Sep; 84(3):635-646. PubMed ID: 31230156
[TBL] [Abstract][Full Text] [Related]
11. Gastrectomy in comprehensive treatment of advanced gastric cancer with synchronous liver metastasis: a prospectively comparative study.
Li Z; Fan B; Shan F; Tang L; Bu Z; Wu A; Zhang L; Wu X; Zong X; Li S; Ren H; Ji J
World J Surg Oncol; 2015 Jul; 13():212. PubMed ID: 26126412
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors in first-line chemotherapy treated metastatic gastric cancer patients: a retrospective study.
Inal A; Kaplan MA; Kuçukoner M; Urakci Z; Guven M; Nas N; Yunce M; Işikdogan A
Asian Pac J Cancer Prev; 2012; 13(8):3869-72. PubMed ID: 23098485
[TBL] [Abstract][Full Text] [Related]
13. Impact of skeletal muscle mass in patients with unresectable gastric cancer who received palliative first-line chemotherapy based on 5-fluorouracil.
Matsunaga T; Saito H; Miyauchi W; Shishido Y; Miyatani K; Morimoto M; Murakami Y; Hanaki T; Kihara K; Yamamoto M; Tokuyasu N; Takano S; Sakamoto T; Hasegawa T; Fujiwara Y
BMC Cancer; 2021 Nov; 21(1):1219. PubMed ID: 34774016
[TBL] [Abstract][Full Text] [Related]
14. Signet Ring Cells and Efficacy of First-line Chemotherapy in Advanced Gastric or Oesogastric Junction Adenocarcinoma.
Lemoine N; Adenis A; Bouche O; Duhamel A; Heurgue A; Leteurtre E; Amela E; Salleron J; Hebbar M
Anticancer Res; 2016 Oct; 36(10):5543-5549. PubMed ID: 27798928
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy.
Kim JG; Ryoo BY; Park YH; Kim BS; Kim TY; Im YH; Kang YK
Cancer Chemother Pharmacol; 2008 Feb; 61(2):301-7. PubMed ID: 17429626
[TBL] [Abstract][Full Text] [Related]
16. A prognostic model to identify patients with advanced pancreas adenocarcinoma who could benefit from second-line chemotherapy.
Kim ST; Choi YJ; Park KH; Oh SC; Seo JH; Shin SW; Kim JS; Kim YH
Clin Oncol (R Coll Radiol); 2012 Mar; 24(2):105-11. PubMed ID: 21382702
[TBL] [Abstract][Full Text] [Related]
17. [FOLFOX regimen in the patients with locally advanced or metastatic gastric cancer].
Yan D; Dai H
Zhonghua Zhong Liu Za Zhi; 2009 Mar; 31(3):217-9. PubMed ID: 19615264
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of βIII-tubulin and survivin associated with drug resistance to docetaxel-based chemotherapy in advanced gastric cancer.
Zheng WE; Chen H; Yuan SF; Wu LL; Zhang W; Sun HY; Chen WJ
J BUON; 2012; 17(2):284-90. PubMed ID: 22740207
[TBL] [Abstract][Full Text] [Related]
19. [Clinical analysis of the current treatment status of gastric cancer in 636 patients].
Zhuang QX; Xu JM; Lin L; Ge FJ; Liu LJ; Wang Y; Zhao CH
Zhonghua Zhong Liu Za Zhi; 2012 Apr; 34(4):316-20. PubMed ID: 22781048
[TBL] [Abstract][Full Text] [Related]
20. A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer.
Ji SH; Lim DH; Yi SY; Kim HS; Jun HJ; Kim KH; Chang MH; Park MJ; Uhm JE; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK
BMC Cancer; 2009 Apr; 9():110. PubMed ID: 19358705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
